Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
Alexander M.M. Eggermont(University Medical Center Utrecht), Stefan Suciu(St James's University Hospital), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Dirk Schadendorf(National Center for Tumor Diseases), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Shahneen Sandhu(The University of Melbourne), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), Stéphane Dalle(Hospices Civils de Lyon), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), James Larkin(Trinity College Dublin), Susana Puig(Instituto de Salud Carlos III), Matteo S. Carlino(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute), Leonel F. Hernandez‐Aya(Washington University in St. Louis), Andrew Haydon(The Alfred Hospital), Caroline Robert(Institut Gustave Roussy), Alfonsus Johannes Maria van den Eertwegh(Radboud University Nijmegen), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Anna Maria Di Giacomo(University of Siena), Victoria Atkinson(Greenslopes Private Hospital), Jean-Jacques Grob(Aix-Marseille Université), Rutger H.T. Koornstra(Radboud University Nijmegen), Adnan Khattak(Edith Cowan University), Mario Mandalà(University of Perugia)
Cited by 439
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k